Medsafe Home Page

Medsafe Home Page
MEDSAFE
New Zealand Medicines and Medical
Devices Safety Authority
Medicines
Medicine
Information
Approval Process
Regulatory
Guidance
Manufacturing
Devices
WAND
Regulatory
Guidance
Surgical Mesh
Safety
Information
Product Recalls
Device Information
Safety
Safety Information
Product Recalls
Safety Communications
Safety
Reporting
Reports
and Promotions
Compliance
Unapproved
Medicines
Product Recalls
Manufacturing
Marketing
Importing
Medicines
Pharmacy
Licensing
Publications
Media
Prescriber
Update
Consultations
Current
Closed
Outcomes
Committees
Medicines Classification
Medicines Assessment
Advisory
Medicines Adverse
Reactions
About Medsafe
Christmas/New Year
Closure
Our Role
What's New
Contact Us
History
Archive
Contact Us
What's New
Prescriber Update 47(1) March 2026
We've published the latest issue of
Prescriber Update
.
This issue contains important safety information about gynaecomastia with medicines, Fournier's gangrene with empagliflozin, zoledronic acid use in elderly patients, and more.
Prescriber Update 47(1) March 2026
Consumers
Consumer Medicine
Information
Personal Importation of Medicines
Consumer Information Leaflets
How to Report a
Problem
Excipients in Medicines
More...
Healthcare Professionals
Data Sheets
Safety Communications
Prescriber Update
How to Report
a Problem
Pharmacy Licence
Register
Approval to Prescribe
Psychedelics
More...
Industry
WAND
Dietary Supplements
Forms and Templates
Regulatory Guidelines
Schedule of Fees
Out of Stock
EFT Access
More...
Database Search
Data Sheets/CMI
Product/Application
for Medicines
Gazette Notices
Adverse
Reactions
Recalls
Classification
Label Statements
News and Events
Date
Type
Title
11/3/2026
Consultation
Consultation on proposed changes to the classification of vitamin D pursuant to the Medicines Regulations 1984
11/3/2026
Committees
Agenda for the 76th Medicines Classification Committee meeting
5/3/2026
Publications
Prescriber Update Vol. 47. No. 1 - March 2026
2/3/2026
Consultation
Outcome of the consultation on the proposal for the package labelling of topical corticosteroids to state their potency
Home
|
About
this Site
|
FAQs
|
Site Map
0
1
2
4
5
6
7
9
[
/